Magnetic resonance imaging‑directed biopsy improves the prediction of prostate cancer aggressiveness compared with a 12‑core transrectal ultrasound‑guided prostate biopsy.

The Gleason grading system is a fundamental indicator of the aggressive nature of prostate cancer (PCa). Diffusion-weighted imaging (DWI) and magnetic resonance (MR) spectroscopy (MRS) are methods for the assessment of PCa aggressiveness. The present study was designed to prospectively investigate whether transrectal ultrasound (TRUS)-guided MR imaging (MRI)-directed biopsies (TRUS‑MR‑Dbs) improve the prediction of PCa aggressiveness in comparison with 12-core TRUS-guided biopsies (TRUS‑Gbs). A total of 518 patients underwent pre-biopsy multi-parametric MRI to identify the clinically suspicious PCa regions. TRUS‑MR‑Dbs were performed on patients with suspected PCa by MRI in addition to TRUS‑Gbs. Only patients who underwent radical prostatectomy (RP) were included in the comparative analysis. TRUS‑biopsy was directed to those areas within suspicious regions with a minimum apparent diffusion coefficient obtained by DWI or with a maximum (choline + creatine)/citrate ratio obtained by MRS. The highest Gleason grades (HGGs) and the Gleason scores (GSs) of specimens were identified. The biopsies and RP results were evaluated using a McNemar test or χ2 analyses using Fisher' exact tests. MRI results were positive in 254 (49.0%) of the 518 patients. TRUS‑MR‑Db detected 165/254 (65.0%) cancer cases and TRUS‑Gb detected 190/518 (36.7%) cancer cases. Forty patients underwent RP. The TRUS‑MR‑Dbs method demonstrated a higher concordance rate (CR) with RP (89.6%) than TRUS‑Gbs (72.9%, P=0.008) for the overall HGG. The CRs with RP for TRUS‑MR‑Dbs vs. those for TRUS‑Gbs were 100 vs. 85.7% (P=0.5), 87.5 vs. 68.8% (P=0.031) and 50 vs. 50% (P=1) for HGG3, HGG4 and HGG5, respectively. The HGG CRs with RP for DWI‑directed biopsies (DWI-Dbs) vs. MRS-directed biopsies (MRS-Dbs) were 77.1 vs. 50.0% (P=0.015) for the overall tumors, 80.0 vs. 40.0% (P=0.003) for peripheral zone tumors and 69.2 vs. 76.9% (P=1) for transition zone tumors. A total of 37 (77.1%) and 25 (52.1%; P=0.007) tumors were assigned accurate GS for TRUS‑MR‑Dbs and TRUS‑Gbs, respectively. The results revealed that TRUS‑MR‑Dbs improved the prediction of PCa aggressiveness and that DWI-Dbs had a superior performance when compared with MRS‑Dbs in the peripheral zone.

[1]  D. Gleason,et al.  Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. , 1974, The Journal of urology.

[2]  L. Egevad,et al.  Prognostic value of the Gleason score in prostate cancer , 2002, BJU international.

[3]  Seymour Rosen,et al.  Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy. , 2003, The Journal of urology.

[4]  J. Kurhanewicz,et al.  Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. , 2005, Radiology.

[5]  M. Kattan,et al.  Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. , 2005, Radiology.

[6]  H. Ozen,et al.  Increasing the number of biopsies increases the concordance of Gleason scores of needle biopsies and prostatectomy specimens. , 2007, Urologic oncology.

[7]  T. Scheenen,et al.  Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility. , 2007, Radiology.

[8]  Jason A Koutcher,et al.  Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging--correlation with pathologic findings. , 2008, Radiology.

[9]  Katsuyoshi Ito,et al.  Apparent diffusion coefficient values in peripheral and transition zones of the prostate: Comparison between normal and malignant prostatic tissues and correlation with histologic grade , 2008, Journal of magnetic resonance imaging : JMRI.

[10]  B. K. Park,et al.  Lesion Localization in Patients With a Previous Negative Transrectal Ultrasound Biopsy and Persistently Elevated Prostate Specific Antigen Level Using Diffusion-Weighted Imaging at Three Tesla Before Rebiopsy , 2008, Investigative radiology.

[11]  Bin Wang,et al.  Diffusion‐weighted imaging of prostate cancer: Correlation between apparent diffusion coefficient values and tumor proliferation , 2009, Journal of magnetic resonance imaging : JMRI.

[12]  Tsuyoshi Mitake,et al.  Real‐time Virtual Sonography for navigation during targeted prostate biopsy using magnetic resonance imaging data , 2010, International journal of urology : official journal of the Japanese Urological Association.

[13]  R. Dhir.  Factors Predicting Prostatic Biopsy Gleason Sum Under Grading , 2010 .

[14]  Bin Wang,et al.  1H-MRSI of prostate cancer: the relationship between metabolite ratio and tumor proliferation. , 2010, European journal of radiology.

[15]  B. K. Park,et al.  Prospective evaluation of 3-T MRI performed before initial transrectal ultrasound-guided prostate biopsy in patients with high prostate-specific antigen and no previous biopsy. , 2011, AJR. American journal of roentgenology.

[16]  Pingkun Yan,et al.  Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. , 2011, The Journal of urology.

[17]  Thomas Hambrock,et al.  In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an endorectal coil. , 2011, European urology.

[18]  P. Box.  Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer , 2011 .

[19]  P. Choyke,et al.  D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging. , 2010, The Journal of urology.

[20]  G. Haber,et al.  Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging‐targeted and systematic biopsy for significant prostate cancer detection , 2011, BJU international.

[21]  François Cornud,et al.  Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2‐weighted, dynamic contrast‐enhanced and diffusion‐weighted imaging , 2011, BJU international.

[22]  S. Verma,et al.  Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. , 2011, AJR. American journal of roentgenology.

[23]  T. Scheenen,et al.  Prostate cancer aggressiveness: in vivo assessment of MR spectroscopy and diffusion-weighted imaging at 3 T. , 2012, Radiology.

[24]  Thomas Hambrock,et al.  Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. , 2012, European urology.

[25]  Baris Turkbey,et al.  Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. , 2012, The Journal of urology.

[26]  Tzu-Ping Lin,et al.  Does extended prostate needle biopsy improve the concordance of Gleason scores between biopsy and prostatectomy in the Taiwanese population? , 2012, Journal of the Chinese Medical Association : JCMA.

[27]  Jianfeng Xu,et al.  Outcomes and Trends of Prostate Biopsy for Prostate Cancer in Chinese Men from 2003 to 2011 , 2012, PloS one.

[28]  Mark Emberton,et al.  Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. , 2013, European urology.

[29]  Naira Muradyan,et al.  Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies. , 2013, The Journal of urology.

[30]  D. Margolis,et al.  Multiparametric Magnetic Resonance Imaging for Prostate Cancer , 2015 .